<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04521868</url>
  </required_header>
  <id_info>
    <org_study_id>Jiangyin-Sulforaphane</org_study_id>
    <nct_id>NCT04521868</nct_id>
  </id_info>
  <brief_title>A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia Patients</brief_title>
  <official_title>A 6-month Study to Evaluate Sulforaphane add-on Effects in Treatment of Negative Symptoms and Cognition Impairment of Schizophrenia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the study is to investigate whether adding sulforaphane will benefit the negative&#xD;
      symptoms and cognitive function in individuals who have schizophrenia.&#xD;
&#xD;
      This study will compare the sulforaphane with placebo. There is a thirty percent change (less&#xD;
      than half) of receiving the placebo. The purpose of including placebo is to judge if the&#xD;
      outcome is related to the study medication rather than other reasons.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be carried out in The Third Jiangyin Hospital in China and total of 120&#xD;
      schizophrenia patients with one negative symptom item score of PANSSâ‰¥3 will be enrolled into&#xD;
      the study. Individuals who participate in the study will be followed for 24 weeks. The&#xD;
      changes in clinical symptoms and neurocognitive function will be assessed from baseline&#xD;
      (week-0) to week-12, and week-24.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 31, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participants and researchers are blind to treatment allocation (double-blind). An independent researcher developed the computer-generated randomization plan.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive improvement assessed using the MATRICS Consensus Cognitive Battery (MCCB) composite score</measure>
    <time_frame>24 weeks</time_frame>
    <description>The investigators will use the MATRICS Consensus Cognitive Battery (MCCB) Composite score as primary cognitive outcome measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of clinical symptoms by PANSS</measure>
    <time_frame>24 weeks</time_frame>
    <description>The change of Positive And Negative Syndrome Scale (PANSS) total, positive and negative symptoms before and after treatment at different follow up point</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>side effects by TESS</measure>
    <time_frame>24 weeks</time_frame>
    <description>The investigators will evaluate side effect by Treatment Emergent Symptom Scale (TESS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of clinical symptoms by SANS</measure>
    <time_frame>24 weeks</time_frame>
    <description>The change of Scale for Assessment of Negative Symptoms (SANS) to evaluate negative symptoms before and after treatment at different follow up point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of clinical symptoms of CGI</measure>
    <time_frame>24 weeks</time_frame>
    <description>The change of Clinical Global Impression (CGI) before and after treatment at different follow up point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of psychological, social, and occupational functioning by GAF</measure>
    <time_frame>24 weeks</time_frame>
    <description>The change of Global Assessment of Functioning (GAF) Scale before and after treatment at different follow up point</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>sulforaphane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The goal of the study is to investigate whether adding sulforaphane will benefit the negative symptoms and cognitive function in individuals who have schizophrenia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulforaphane</intervention_name>
    <description>Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.</description>
    <arm_group_label>sulforaphane</arm_group_label>
    <other_name>Nutramax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo is made of starch</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Meet The Diagnostic and Statistical Manual (DSM-5) diagnostic criteria for&#xD;
             schizophrenia 2. First onset or duration of illness less than 30 years with current&#xD;
             symptoms in a stable condition 3. Male and female with aged 17 to 50 years 4. an item&#xD;
             of PANSS negative symptoms &gt;3 scores. 5. Signed the study consent for participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. having history of substance dependence or abuse or whose symptoms are caused by the&#xD;
             other diagnosable mental disorders; 2. having history of traumatic brain injury,&#xD;
             seizures or other known neurological or organic diseases of the central nervous&#xD;
             system; 3. taking antidepressants, stimulants, mood stabilizer or accepts electricity&#xD;
             shock treatment; 4. having current suicidal or homicidal thoughts or any safety&#xD;
             concern by research staff that cannot be manage in an inpatient setting; 5. taking&#xD;
             dementia-related drugs, minocycline, and other drugs that could affect cognitive&#xD;
             function.&#xD;
&#xD;
             6. the routine blood tests showing significant abnormal renal, liver function or other&#xD;
             metabolic results.&#xD;
&#xD;
             6. pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renrong Wu, M.D Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renrong Wu</last_name>
    <phone>+8615874179855</phone>
    <email>wurenrong@csu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Huang</last_name>
    <phone>+8615874290980</phone>
    <email>jinghuangserena001@csu.edu.cn</email>
  </overall_contact_backup>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central South University</investigator_affiliation>
    <investigator_full_name>Renrong Wu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>sulforaphane</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulforaphane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

